PIK3CA and cancer: Given the difference between these results and the evidence from colorectal cancer, which suggests longer survival among patients with PIK3CA mutation who used aspirin, our study emphasizes the importance of further investigation of the complex effects of aspirin/NSAID use, tumor genomic subtypes and cancer progression, with both observational and randomized studies.